Why is GSK stock sliding today?
GSK plc's stock fell 4.6% after its Q3 2026 earnings report, despite beating EPS and sales estimates. Vaccine revenues declined, and operating profit dropped 16%. The company expects lower core EPS growth for the year. Barclays maintained a Sell rating, and the FTSE 100's decline added to the pressure, pushing GSK shares to an intraday low of 1823p.
How this was made
The 30-second read
Why it matters
The earnings surprise and guidance downgrade triggered a 4.6% intraday decline, highlighting investor sensitivity to vaccine revenue trends.
Market read
The earnings release is the primary catalyst for GSK's share slide and may influence broader pharma sentiment.
What to watch
Potential upside from upcoming pipeline products and long‑term vaccine contracts not reflected in the short‑term numbers.
Background
GSK's Q3 results were released before the London open, showing mixed performance with core EPS beat but weaker vaccine sales and higher financing costs.
Ticker impact
GSK reported Q3 2026 earnings with core EPS beat but vaccine revenue decline and lower‑half guidance, causing a 4.6% share drop.
likely further downside as investors price in weaker guidance and higher debt costs
The earnings release includes new guidance and a restructuring charge that were not previously public, and the stock already fell 4.6% intraday.
Market effects
Healthcare sector may face pressure as vaccine revenue concerns spread to peers.
UK market sentiment weakened, dragging FTSE 100 lower.
Limited to GSK and related vaccine manufacturers; no broad macro impact.
Counterpoint
If the market overreacts to short‑term vaccine dip, the stock could rebound on solid core earnings.
Key entities
- companyGSK plc
British pharmaceutical giant reporting Q3 2026 earnings.
